Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Zydus Lifesciences Limited Press Release Jan 30 2024

· Issued by Zydus Lifesciences Limited via NSE India

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing the launch of Rexigo™, an oral once-a-day pill for advanced prostate cancer patients in India. This therapy is significant as it suppresses testosterone levels, providing a more convenient alternative to previous injectable treatments. Rexigo™ is the first generic oral option available in India, making it both accessible and affordable for patients. The launch marks a major advancement in prostate cancer management, offering improved safety and quality of life for patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 30, 2024, titled "Zydus Lifesciences launches Rexigo , the oral once-a-day pill for advanced prostate cancer patients in India".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases